Dissecting cell type-specific metabolism in pancreatic ductal adenocarcinoma
- Massachusetts Institute of Technology, United States
- University of Massachusetts, Amherst, United States
- Harvard Medical School, United States
- Cold Spring Harbor Laboratory, United States
- University of Cambridge, United Kingdom
Abstract
Tumors are composed of many different cell types including cancer cells, fibroblasts, and immune cells. Dissecting functional metabolic differences between cell types within a mixed population can be challenging due to the rapid turnover of metabolites relative to the time needed to isolate cells. To overcome this challenge, we traced isotope-labeled nutrients into macromolecules that turn over more slowly than metabolites. This approach was used to assess differences between cancer cell and fibroblast metabolism in murine pancreatic cancer organoid-fibroblast co-cultures and tumors. Pancreatic cancer cells exhibited increased pyruvate carboxylation relative to fibroblasts, and this flux depended on both pyruvate carboxylase and malic enzyme 1 activity. Consequently, expression of both enzymes in cancer cells was necessary for organoid and tumor growth, demonstrating that dissecting the metabolism of specific cell populations within heterogeneous systems can identify dependencies that may not be evident from studying isolated cells in culture or bulk tissue.
Data availability
All data generated or analyzed during this study are included in the manuscript and supporting files.
Article and author information
Author details
Nicholas J Matheson
Matthew G Vander Heiden
Funding
Damon Runyon Cancer Research Foundation (DRG-2241-15)
- Allison N Lau
National Cancer Institute (U54CA163109)
- Vasilena Gocheva
Human Frontiers Science Program (LT000195/2015-L)
- Giulia Biffi
EMBO (ALTF 1203-2014)
- Giulia Biffi
Howard Hughes Medical Institute
- Tyler Jacks
- Matthew G Vander Heiden
MRC (CSF MR/P008801/1)
- Nicholas J Matheson
NHSBT (WPA15-02)
- Nicholas J Matheson
NIHR Cambridge BRC
- Nicholas J Matheson
National Institutes of Health (R01CA211184)
- Omer Yilmaz
National Institutes of Health (R01CA034992)
- Omer Yilmaz
Lustgarten Foundation
- Matthew G Vander Heiden
Damon Runyon Cancer Research Foundation (DRG-2367-19)
- Sharanya Sivanand
Stand Up To Cancer
- Matthew G Vander Heiden
MIT Center for Precision Cancer Medicine
- Matthew G Vander Heiden
Ludwig Center at MIT
- Tyler Jacks
- Matthew G Vander Heiden
Emerald Foundation
- Matthew G Vander Heiden
National Cancer Institute (R01CA168653)
- Matthew G Vander Heiden
National Cancer Institute (R01CA201276)
- Matthew G Vander Heiden
National Cancer Institute (R35CA242379)
- Matthew G Vander Heiden
National Cancer Institute (P30CA14051)
- Matthew G Vander Heiden
Damon Runyon Cancer Research Foundation (DRG-2299-17)
- Evan C Lien
National Cancer Institute (K99CA234221)
- Allison N Lau
National Institutes of Health (T32GM007287)
- Zhaoqi Li
- Kiera M Sapp
Jane Coffin Childs Memorial Fund for Medical Research
- Alicia M Darnell
- Vasilena Gocheva
Swedish Foundation for Strategic Research
- Raphael Ferreira
Knut and Alice Wallenberg Foundation
- Raphael Ferreira
Barbro Osher Pro Suecia Foundation
- Raphael Ferreira
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All animal studies were approved by the MIT Committee on Animal Care under protocol #0119-001-22.
Reviewing Editor
- Ralph DeBerardinis, UT Southwestern Medical Center, United States
Version history
- Received: March 9, 2020
- Accepted: July 9, 2020
- Accepted Manuscript published: July 10, 2020 (version 1)
- Version of Record published: August 5, 2020 (version 2)
Copyright
© 2020, Lau et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 6,587
- Page views
-
- 1,178
- Downloads
-
- 51
- Citations
Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Dissecting cell type-specific metabolism in pancreatic ductal adenocarcinoma
eLife 9:e56782.
https://doi.org/10.7554/eLife.56782
Further reading
-
- Cancer Biology
Cancer stem cells (CSCs) undergo epithelial-mesenchymal transition (EMT) to drive metastatic dissemination in experimental cancer models. However, tumour cells undergoing EMT have not been observed disseminating into the tissue surrounding human tumour specimens, leaving the relevance to human cancer uncertain. We have previously identified both EpCAM and CD24 as CSC markers that, alongside the mesenchymal marker Vimentin, identify EMT CSCs in human oral cancer cell lines. This afforded the opportunity to investigate whether the combination of these three markers can identify disseminating EMT CSCs in actual human tumours. Examining disseminating tumour cells in over 12,000 imaging fields from 74 human oral tumours, we see a significant enrichment of EpCAM, CD24 and Vimentin co-stained cells disseminating beyond the tumour body in metastatic specimens. Through training an artificial neural network, these predict metastasis with high accuracy (cross-validated accuracy of 87-89%). In this study, we have observed single disseminating EMT CSCs in human oral cancer specimens, and these are highly predictive of metastatic disease.
-
- Cancer Biology
- Medicine
Esophageal cancer (EC) is a fatal digestive disease with a poor prognosis and frequent lymphatic metastases. Nevertheless, reliable biomarkers for EC diagnosis are currently unavailable. Accordingly, we have performed a comparative proteomics analysis on cancer and paracancer tissue-derived exosomes from eight pairs of EC patients using label-free quantification proteomics profiling and have analyzed the differentially expressed proteins through bioinformatics. Furthermore, nano-flow cytometry (NanoFCM) was used to validate the candidate proteins from plasma-derived exosomes in 122 EC patients. Of the 803 differentially expressed proteins discovered in cancer and paracancer tissue-derived exosomes, 686 were up-regulated and 117 were down-regulated. Intercellular adhesion molecule-1 (CD54) was identified as an up-regulated candidate for further investigation, and its high expression in cancer tissues of EC patients was validated using immunohistochemistry, real-time quantitative PCR (RT-qPCR), and western blot analyses. In addition, plasma-derived exosome NanoFCM data from 122 EC patients concurred with our proteomic analysis. The receiver operating characteristic (ROC) analysis demonstrated that the AUC, sensitivity, and specificity values for CD54 were 0.702, 66.13%, and 71.31%, respectively, for EC diagnosis. Small interference (si)RNA was employed to silence the CD54 gene in EC cells. A series of assays, including cell counting kit-8, adhesion, wound healing, and Matrigel invasion, were performed to investigate EC viability, adhesive, migratory, and invasive abilities, respectively. The results showed that CD54 promoted EC proliferation, migration, and invasion. Collectively, tissue-derived exosomal proteomics strongly demonstrates that CD54 is a promising biomarker for EC diagnosis and a key molecule for EC development.
